Clinical Study
Adding Bismuth to Rabeprazole-Based First-Line Triple Therapy Does Not Improve the Eradication of Helicobacter pylori
Table 5
Univariate analysis of clinical factors which might influence the efficacy of the RAK and RBAK.
| | Eradication rate, n/N (%) | RAK | RBAK | value |
| | Resistance to | | Metronidazole | | ITT and PP | 6/11 (54.5) | 7/11 (63.6) | 1.00 | | Clarithromycin | | ITT and PP | 2/5 (40.0) | 1/5 (20.0) | 1.00 | | Tetracycline | — | — | — | | Levofloxacin | 3/3 (100) | 3/6 (50.0) | 0.46 | | Amoxicillin | 1/1 (100) | 1/1 (100) | 1.00 | | Dual resistance¶ | | Present | | ITT | 3/5 (60.0) | 3/5 (60.0) | 1.00 | | PP | 3/5 (60.0) | 3/4 (75.0) | 1.00 | | Absent | | ITT | 27/33 (81.8) | 27/38 (71.1) | 0.29 | | PP | 27/31 (87.1) | 27/35 (77.1) | 0.30 | | Adverse events | | Present | 25/36 (69.4) | 34/41 (82.9) | 0.16 | | Absent | 31/40 (77.5) | 29/40 (72.5) | 0.61 | | Compliance | | Good | 58/80 (72.5) | 63/81 (77.8) | 0.44 | | Poor | 1/1 (100) | 0/0 (0.0) | — | | Smoking | | Present | 17/23 (73.9) | 15/20 (75.0) | 0.94 | | Absent | 42/58 (72.4) | 48/61 (78.7) | 0.42 |
|
|
Fisher exact test. ¶Dual resistance was defined as presence of any two of the five antibiotics.
|
